Update on kidney transplantation in HIV-infected recipients

AIDS Reviews

Volumn 14, Issue 3, 2012, Pages 195-207

  Norman, Silas P ^a   Kommareddi, Mallika ^a   Kaul, Daniel R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

End stage renal disease; HIV; Immunosuppression; Kidney transplant

Indexed keywords

ABACAVIR; ALEMTUZUMAB; ATAZANAVIR; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOSPORIN A; DACLIZUMAB; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; EVEROLIMUS; INDINAVIR; INTERLEUKIN 2 RECEPTOR ANTIBODY; LAMIVUDINE; MARAVIROC; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NYSTATIN; PREDNISONE; PROTEINASE INHIBITOR; RALTEGRAVIR; RAPAMYCIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; STEROID; TACROLIMUS; TENOFOVIR; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VALGANCICLOVIR; ZIDOVUDINE;

CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL RESEARCH; CYTOMEGALOVIRUS INFECTION; DISEASE REGISTRY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; GLUCOSURIA; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH CARE QUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MYCOSIS; OBSTRUCTIVE UROPATHY; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PREVALENCE; PROTEINURIA; RENAL REPLACEMENT THERAPY; REVIEW; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; PATIENT SELECTION; REFERRAL AND CONSULTATION; UNITED STATES;

EID: 84864693538     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Stock P, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363:2004-14.
2. Jensen-Fangel S, Pedersen L, Pedersen C, et al. Low mortality in HIVinfected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS. 2004;18:89-97. (Pubitemid 38402322)
3. Bonnet F, Lewden C, May T, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer. 2004;101:317-24. (Pubitemid 38890835)
4. Wyatt C, Murphy B. Kidney transplantation in HIV-infected patients. Semin Dial. 2005;18:495-8. (Pubitemid 43094227)
5. Centers for Disease Control and Prevention. HIV and AIDS in the United States. Fact Sheet. http://www.cdc.gov/hiv/resources/factsheets/PDF/us.pdf. July, 2010.
6. Kimmel P. The nephropathies of HIV infection: pathogenesis and treatment. Curr Opin Nephrol Hypertens. 2000;9:117-22. (Pubitemid 30131441)
7. Herman E, Klotman P. HIV-associated nephropathy: Epidemiology, pathogenesis, and treatment. Semin Nephrol. 2003;23:200-8. (Pubitemid 36397102)
8. Kopp J, Winkler C. HIV-associated nephropathy in African Americans. Kidney Int Suppl. 2003:S43-9. (Pubitemid 36126842)
9. U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009.
10. Stokes M, Chawla H, Brody R, et al. Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus. Am J Kidney Dis. 1997;29:514-25. (Pubitemid 27155271)
11. Nochy D, Glotz D, Dosquet P, et al. Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol Dial Transplant. 1993;8:11-19. (Pubitemid 23050590)
12. Nagy Z, Uj M, Szucs G, Nagy J. HIV and IgA nephropathy. Nephrol Dial Transplant. 1996;11:906-7.
13. Ockenga J, Tillmann H, Trautwein C, Stoll M, Manns M, Schmidt R. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol. 1997;27:18-24. (Pubitemid 27357049)
14. Fine D, Perazella M, Lucas G, Atta M. Renal disease in patients with HIV infection: epidemiology, pathogenesis and management. Drugs. 2008;68:963-80. (Pubitemid 351652924)
15. Currier J, Havlir D. Complications of HIV disease and antiretroviral therapy. Highlights of the 11th CROI, 2004, San Francisco, California, USA. Top HIV Med. 2004;12:31-45.
16. Kopp J, Miller K, Mican J, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127:119-25. (Pubitemid 27337395)
17. Gupta S, Eustace J, Winston J, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-85. (Pubitemid 40720806)
18. Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26:867-75.
19. Cooper R, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496-505.
20. Pelletier S, Norman S, Christensen L, Stock P, Port F, Merion R. Review of transplantation in HIV patients during the HAART era. Clin Transpl. 2004:63-82.
21. Sawinski D, Wyatt C, Casagrande L, et al. Factors associated with failure to list HIV-positive kidney transplant candidates. Am J Transplant. 2009;9:1467-71.
22. Wolfe R, Ashby V, Milford E, et al. Differences in access to cadaveric renal transplantation in the United States. Am J Kidney Dis. 2000;36:1025-33.
23. Ahuja T, Borucki M, Grady J. Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients. Am J Kidney Dis. 2000;36:574-80.
24. Ahuja T, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol. 2002;13:1889-93. (Pubitemid 34700614)
25. U.S. Renal Data System, USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004.
26. Murphy E, Collier A, Kalish L, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135:17-26. (Pubitemid 32619279)
27. Roland M, Carlson L, Ragni M, et al. Solid organ transplantation in HIVinfected recipients: A review of 53 cases in the HAART-era [abstract]. In: XIV International AIDS Conference 2002. Barcelona, Spain; 2002.
28. Roefs A, van der Ende M, IJzermans J, Weimar W, van Gelder T. Longterm survival after kidney transplantation in an HIV-positive patient. Clin Transplant. 2009,23:278-81.
29. Abbott K, Swanson S, Agodoa L, Kimmel P. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol. 2004;15:1633-9. (Pubitemid 38679689)
30. Locke J, Montgomery R, Warren D, Subramanian A, Segev D. Renal transplant in HIV-positive patients: long-term outcomes and risk factors for graft loss. Arch Surg. 2009;144:83-6.
31. Gruber S, Doshi M, Cincotta E, et al. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation. 2008;86:269-74.
32. Fan P, Ashby V, Fuller D, et al. Access and outcomes among minority transplant patients, 1999-2008, with a focus on determinants of kidney graft survival. Am J Transplant. 2010;10:1090-107.
33. Connolly N, Riddler S, Rinaldo C. Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches. AIDS Rev. 2005;7:168-80. (Pubitemid 41671917)
34. Fernandez S, Lim A, French M. Immune activation and the pathogenesis of HIV disease: implications for therapy. J HIV Ther. 2009;14:52-6.
35. Rouse B, Sehrawat S. Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol. 2010;10:514-26.
36. Benito J, Lopez M, Lozano S, et al. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2005;38:373-81.
37. Brenchley J, Price D, Schacker T, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-71. (Pubitemid 44924494)
38. Stoiber H, Soederholm A, Wilflingseder D, Gusenbauer S, Hildgartner A, Dierich M. Complement and antibodies: a dangerous liaison in HIV infection? Vaccine. 2008;26(Suppl 8):I79-85.
39. Picker L, Watkins D. HIV pathogenesis: the first cut is the deepest. Nat Immunol. 2005;6:430-2. (Pubitemid 41716753)
40. Franke E, Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology. 1996;222:279-82. (Pubitemid 26281382)
41. Wiegers K, Krausslich H. Differential dependence of the infectivity of HIV-1 group O isolates on the cellular protein cyclophilin A. Virology. 2002;294:289-95. (Pubitemid 34920527)
42. Streblow D, Kitabwalla M, Malkovsky M, Pauza C. Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A. Virology. 1998;245:197-202. (Pubitemid 28394182)
43. Braaten D, Franke E, Luban J. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol. 1996;70:3551-60. (Pubitemid 26157335)
44. Alkhatib G, Locati M, Kennedy P, Murphy P, Berger E. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology. 1997;234:340-8. (Pubitemid 27360126)
45. Briggs C, Tozser J, Oroszlan S. Effect of cyclosporin A on the replication cycle of human immunodeficiency virus type 1 derived from H9 and Molt-4 producer cells. J Gen Virol. 1996;77:2963-7. (Pubitemid 27056516)
46. Sekigawa I, Koshino K, Hishikawa T, et al. Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120. J Clin Immunol. 1995;15:312-17.
47. Briggs C, Ott D, Coren L, Oroszlan S, Tozser J. Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. Arch Virol. 1999;144:2151-60.
48. Heredia A, Amoroso A, Davis C, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA. 2003;100:10411-16. (Pubitemid 37071892)
49. Andrieu J, Even P, Venet A, et al. Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease. Clin Immunol Immunopathol. 1988;47:181-98.
50. Erice A, Rhame F, Heussner R, Dunn D, Balfour H. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis. 1991;13:537-47.
51. Rizzardi G, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest. 2002;109:681-8. (Pubitemid 34204847)
52. 2008 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998-2007. U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD.
53. Trullas J, Cofan F, Cocchi S, et al. Effect of thymoglobulin induction on HIV-infected renal transplant recipients: differences between HIV-positive and HIV-negative patients. AIDS Res Hum Retroviruses. 2007;23:1161-5. (Pubitemid 350014766)
54. Brennan D, Flavin K, Lowell J, et al. Leukocyte response to thymoglobulin or atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients. Transplant Proc. 1999;31:16-18S.
55. Stock P, Roland M, Carlson L, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation. 2003;76:370-5. (Pubitemid 36928001)
56. Billault C, Duvivier C, Valantin M, et al. Kidney transplantation in HIV-positive patients: report of our first 7 cases. Transplant Proc. 2009;41:3301-4.
57. Dinavahi R, Mehrotra A, Murphy B, Huprikar S. Human immunodeficiency virus and renal transplantation. Kidney Int. 2009;76:907-10.
58. Tan H, Kaczorowski D, Basu A, et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation. 2004;78:1683-8. (Pubitemid 39648444)
59. Roland M, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8:355-65.
60. Marfo K, Greenstein S. Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplant Proc. 2009;41:3796-9.
61. Christians U, Jacobsen W, Benet L, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002;41:813-851.
62. Sheikh A, Wolf D, Lebovics E, Goldberg R, Horowitz H. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation. 1999;68:307-9. (Pubitemid 29360297)
63. Neff G, Bonham A, Tzakis A, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl. 2003;9:239-47. (Pubitemid 36322325)
64. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077-80. (Pubitemid 23099291)
65. Jain A, Venkataramanan R, Fridell J, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. 2002;8:838-40. (Pubitemid 35012296)
66. Hariparsad N, Nallani S, Sane R, Buckley D, Buckley A, Desai P. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004;44:1273-81. (Pubitemid 39391486)
67. The Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2012.
68. Chapuis A, Paolo Rizzardi G, D'Agostino C, et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med. 2000;6:762-8. (Pubitemid 30469424)
69. Coull J, Turner D, Melby T, Betts M, Lanier R, Margolis D. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr. 2001;26:423-34. (Pubitemid 32489020)
70. Andrieu J, Lu W, Levy R. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis. 1995;171:523-30.
71. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2001;40:723-51. (Pubitemid 33027888)
72. Christiaans M, van Duijnhoven E, Beysens T, Undre N, Schafer A, van Hooff J. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc. 1998;30:1271-3. (Pubitemid 28309568)
73. Davis C. Preemptive transplantation and the transplant first initiative. Curr Opin Nephrol Hypertens 2010,19:592-597.
74. Solid organ transplantation in the HIV-infected patient. Am J Transplant. 2004;4(Suppl 10):83-8.